News
NTLA
14.16
-5.22%
-0.78
Weekly Report: what happened at NTLA last week (0406-0410)?
Weekly Report · 3d ago
Intellia Therapeutics Adopts Fourth Amended and Restated Bylaws
TipRanks · 6d ago
Intellia bylaws set US federal courts as exclusive forum for Securities Act claims
Reuters · 6d ago
Weekly Report: what happened at NTLA last week (0330-0403)?
Weekly Report · 04/06 09:54
Intellia grants 67,150 inducement RSUs to 13 new employees under 2024 plan
Reuters · 04/03 20:05
INTELLIA THERAPEUTICS REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 04/03 20:05
CRISPR Therapeutics: The Fundamental Standard-Bearer in a Fractured Genomic Sector
Barchart · 03/31 07:07
Weekly Report: what happened at NTLA last week (0323-0327)?
Weekly Report · 03/30 09:55
Bank of America Securities Reaffirms Their Hold Rating on Intellia Therapeutics (NTLA)
TipRanks · 03/24 10:20
Weekly Report: what happened at NTLA last week (0316-0320)?
Weekly Report · 03/23 09:52
Caribou Biosciences: Antlers Up For The Allogenic CAR-T Bet Trading At Cash Value
Seeking Alpha · 03/17 13:38
Weekly Report: what happened at NTLA last week (0309-0313)?
Weekly Report · 03/16 09:51
KalVista Pharmaceuticals: Has Potential But With Caveats
Seeking Alpha · 03/12 15:07
Is A Vertex Buyout Of Crispr Therapeutics Inevitable? Here's My Take
Seeking Alpha · 03/09 20:07
Intellia Therapeutics: Why The Clinical Hold Lift Isn't A Total Victory
Seeking Alpha · 03/09 15:28
Cathie Wood's weekly recap: adds to AMZN, BABA, HOOD, COIN, cuts TSM, BIDU
Seeking Alpha · 03/09 11:10
Weekly Report: what happened at NTLA last week (0302-0306)?
Weekly Report · 03/09 09:52
Intellia Therapeutics Awards 16,500 RSU Inducement Grants Under 2024 Plan
Reuters · 03/06 21:01
INTELLIA THERAPEUTICS REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 03/06 21:01
Most and least shorted small-to-mid-cap stocks
Seeking Alpha · 03/05 15:05
More
Webull provides a variety of real-time NTLA stock news. You can receive the latest news about Intellia Therape through multiple platforms. This information may help you make smarter investment decisions.
About NTLA
Intellia Therapeutics, Inc. is a clinical-stage gene editing company focused on developing medicine with CRISPR-based therapies and other core technologies. CRISPR/Cas9 is a gene editing technology that leverages the body’s natural processes to precisely edit DNA. The Company is developing lonvoguran ziclumeran (lonvo-z), referred to as NTLA-2002, for the treatment of hereditary angioedema (HAE) and nexiguran ziclumeran (nex-z) also referred to as NTLA-2001, for the treatment of transthyretin (ATTR) amyloidosis. It is focused on completing late-stage clinical development of its lead product candidates, lonvo-z for the treatment of patients with HAE and nex-z for the treatment of patients with ATTR amyloidosis with cardiomyopathy (ATTR-CM) and hereditary ATTR amyloidosis with polyneuropathy (ATTRv-PN). Its lead product candidates are the first in vivo genome editing product candidates into Phase III development. Its other pipeline products include REGV131-LNP1265 and AVC-201 & AVC-203.